Over the past decades, NSCLC management has evolved from conventional therapy to personalized targeted therapy using small-molecule inhibitors and antibodies for tumors harboring certain genetic aberrations in oncogenic drivers, such as EGFR, ALK, ROS1, BRAF and other genes, in cancer cells, mainly in lung adenocarcinomas [11,12]. Here, EGFR is linked to lung adenocarcinoma.